‘How do you decide?’: Cancer therapy's CAR-T crisis has patients dying on a waitlist By Angus Chen MD Anderson Cancer Center Within two years of being diagnosed with multiple myeloma, Shawn Goltzene (above) had blasted through nearly all his options. His clinician saw only one possibility left to save his life — a newly approved CAR-T cell therapy. But the shortage of CAR-T therapy for multiple myeloma is creating a gut-wrenching dilemma for clinicians: Doctors must decide which of their dozens of eligible patients will get one of a few coveted CAR-T spots each month. Read More |
No comments